MCID: LYM020
MIFTS: 40

Lymph Node Cancer

Categories: Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Lymph Node Cancer

MalaCards integrated aliases for Lymph Node Cancer:

Name: Lymph Node Cancer 12 15 73
Lymph Node Neoplasm 12 53
Neoplasm of Lymph Node 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10619
NCIt 50 C35497
SNOMED-CT 68 127232002

Summaries for Lymph Node Cancer

Disease Ontology : 12 A lymphatic system cancer that is located in the lymph node.

MalaCards based summary : Lymph Node Cancer, also known as lymph node neoplasm, is related to lymphoma, hodgkin, classic and lymph node adenoid cystic carcinoma. An important gene associated with Lymph Node Cancer is SCG2 (Secretogranin II), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and DNA Damage. The drugs Nilutamide and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include the lymph node, lymph node and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymph Node Cancer

Graphical network of the top 20 diseases related to Lymph Node Cancer:



Diseases related to Lymph Node Cancer

Symptoms & Phenotypes for Lymph Node Cancer

GenomeRNAi Phenotypes related to Lymph Node Cancer according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.74 WWOX
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.74 WWOX
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.74 IGF1R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.74 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.74 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.74 WWOX
7 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.74 IGF1R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.74 WWOX
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.74 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.74 WWOX
11 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 WWOX IGF1R TP53
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.74 IGF1R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.74 TP53 WWOX
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.74 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 IGF1R
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.74 IGF1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.74 TP53
18 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.74 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 IGF1R
20 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.74 IGF1R
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.74 WWOX
22 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.74 IGF1R
23 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.74 IGF1R
24 Increased cell death HMECs cells GR00103-A-0 9.35 IGF1R KCNA3 PLAUR TP53 WWOX

MGI Mouse Phenotypes related to Lymph Node Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.8 FOS IGF1R IGFBP3 KCNA3 PLAUR TP53
2 homeostasis/metabolism MP:0005376 9.7 FOS IGF1R IGFBP3 KCNA3 PLAUR TP53
3 liver/biliary system MP:0005370 9.35 IGF1R IGFBP3 PLAUR TP53 WWOX
4 muscle MP:0005369 9.02 IGFBP3 KCNA3 PLAUR TP53 IGF1R

Drugs & Therapeutics for Lymph Node Cancer

Drugs for Lymph Node Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nilutamide Approved, Investigational Phase 3 63612-50-0 4493
2
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
3
Abiraterone acetate Phase 3 154229-18-2 57336518
4 Androgen Antagonists Phase 3
5 Androgens Phase 3
6 Anti-Inflammatory Agents Phase 3,Not Applicable
7 Antineoplastic Agents, Hormonal Phase 3,Not Applicable
8 Cytochrome P-450 Enzyme Inhibitors Phase 3
9 glucocorticoids Phase 3,Not Applicable
10 Hormone Antagonists Phase 3,Not Applicable
11 Hormones Phase 3,Not Applicable
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Not Applicable
13 Steroid Synthesis Inhibitors Phase 3
14
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
15
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
16 Histone Deacetylase Inhibitors Phase 1, Phase 2
17
Dacarbazine Approved, Investigational Phase 1 4342-03-4 5351166
18
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
19
nivolumab Approved Phase 1 946414-94-4
20 Alkylating Agents Phase 1
21 Antineoplastic Agents, Alkylating Phase 1
22 Antibodies Phase 1
23 Antibodies, Monoclonal Phase 1
24 Immunoglobulins Phase 1
25
Hydrocortisone Approved, Vet_approved Not Applicable 50-23-7 5754
26
Capecitabine Approved, Investigational 154361-50-9 60953
27
Oxaliplatin Approved, Investigational 61825-94-3 5310940 9887054 43805 6857599
28
Iron Approved Not Applicable 7439-89-6 23925
29
Pancrelipase Approved, Investigational 53608-75-6
30
Dexamethasone Approved, Investigational, Vet_approved Not Applicable 50-02-2 5743
31
Levoleucovorin Approved, Investigational Not Applicable 68538-85-2
32
Methotrexate Approved Not Applicable 1959-05-2, 59-05-2 126941
33
Zidovudine Approved Not Applicable 30516-87-1 35370
34
Choline Approved, Nutraceutical Not Applicable 62-49-7 305
35
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
36
leucovorin Approved, Nutraceutical Not Applicable 58-05-9 143 6006
37 Antimetabolites Not Applicable
38 Cortisol succinate Not Applicable
39 Gastrointestinal Agents Not Applicable
40 Hydrocortisone 17-butyrate 21-propionate Not Applicable
41 Hydrocortisone acetate Not Applicable
42 Hypolipidemic Agents Not Applicable
43 Lipid Regulating Agents Not Applicable
44 Nootropic Agents Not Applicable
45 Antimetabolites, Antineoplastic ,Not Applicable
46 Ferrosoferric Oxide Not Applicable
47 Hematinics Not Applicable
48 Parenteral Nutrition Solutions Not Applicable
49 Pharmaceutical Solutions Not Applicable
50 pancreatin

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms Active, not recruiting NCT02403505 Phase 3 ABIRATERONE - Group 1;ABIRATERONE - Group 2
2 A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology Completed NCT01667536 Phase 2 Drug: 99mTc-MIP-1404
3 Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting NCT02638090 Phase 1, Phase 2 Vorinostat;Pembrolizumab
4 PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01500733 Phase 2 PCI 32765
5 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Recruiting NCT03426891 Phase 1 Pembrolizumab;Vorinostat;Temozolomide
6 Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) Recruiting NCT02973113 Phase 1
7 Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases Active, not recruiting NCT01447056 Phase 1
8 [18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases Unknown status NCT00670527 Not Applicable
9 Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial Unknown status NCT02298010 Capecitabine, oxaliplatin
10 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study Completed NCT01927887 Not Applicable Ferumoxytol
11 Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer Completed NCT02156414
12 Videoscopic Ilioinguinal Lymphadenectomy for Melanoma Completed NCT02508909 Not Applicable
13 Clinical Impact of EUS Elastography Mean Strain Histograms (SH) and Contrast Peak-enhancement in Focal Pancreatic Masses and Lymph Nodes Completed NCT02459041
14 Tissue Characterisation by Endoscopic GI-elastography Completed NCT01360411
15 High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients Recruiting NCT02570399 Not Applicable
16 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer Recruiting NCT00039676
17 Family Study of Lymphoproliferative Disorders Recruiting NCT00626496
18 Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level Recruiting NCT02555592
19 Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging Active, not recruiting NCT01815333 Not Applicable Feraheme
20 Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer Active, not recruiting NCT01737619 Not Applicable
21 Negative Pressure Wound Therapy in Groin Dissection Not yet recruiting NCT02408835 Not Applicable
22 The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer Terminated NCT00000723 Not Applicable Methotrexate;Leucovorin calcium;Zidovudine;Dexamethasone
23 Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy Withdrawn NCT02752009 Not Applicable

Search NIH Clinical Center for Lymph Node Cancer

Genetic Tests for Lymph Node Cancer

Anatomical Context for Lymph Node Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Lymph Node Cancer:

19
The Lymph Node

MalaCards organs/tissues related to Lymph Node Cancer:

41
Lymph Node, Prostate, Lung, T Cells, Thyroid

Publications for Lymph Node Cancer

Articles related to Lymph Node Cancer:

# Title Authors Year
1
Lymph node cancer of the mediastinum with a putative necrotic primary lesion in the lung: a case report. ( 29606126 )
2018
2
Lymph node cancer of the mediastinal or hilar region with an unknown primary site. ( 7898117 )
1995
3
CT of cervical lymph node cancer. ( 6781263 )
1981

Variations for Lymph Node Cancer

Expression for Lymph Node Cancer

Search GEO for disease gene expression data for Lymph Node Cancer.

Pathways for Lymph Node Cancer

Pathways related to Lymph Node Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.33 FOS IGF1R IGFBP3 PLAUR
2 12.08 FOS TP53 WWOX
3 11.8 IGF1R PLAUR TP53
4
Show member pathways
11.6 FOS PLAUR TP53
5 11.6 IGF1R IGFBP3 TP53
6
Show member pathways
11.57 FOS TP53
7 11.3 IGF1R PLAUR
8
Show member pathways
11.23 IGF1R IGFBP3 TP53
9 11.16 FOS TP53
10 11.08 FOS PLAUR
11 10.94 IGFBP3 TP53
12 10.82 IGF1R IGFBP3 TP53

GO Terms for Lymph Node Cancer

Cellular components related to Lymph Node Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.8 IGFBP3 PLAUR SCG2

Biological processes related to Lymph Node Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tetramerization GO:0051262 9.26 IGF1R TP53
2 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.16 TP53 WWOX
3 positive regulation of release of cytochrome c from mitochondria GO:0090200 8.96 PLAUR TP53
4 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.62 FOS TP53

Molecular functions related to Lymph Node Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor binding GO:0005520 8.96 IGF1R IGFBP3
2 insulin-like growth factor I binding GO:0031994 8.62 IGF1R IGFBP3

Sources for Lymph Node Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....